TOP > 外国特許検索 > PEPTIDES IMPARTING CELL PERMEABILITY TO LIPID MEMBRANE STRUCTURE AND/OR ENHANCING CELL PERMEABILITY OF LIPID MEMBRANE STRUCTURE, AND LIPID MEMBRANE STRUCTURE COMPRISING LIPID BOUND TO SUCH PEPTIDE AS CONSTITUENT LIPID AND HAVING CELL PERMEABILITY OR SHOWING ENHANCED CELL PERMEABILITY

PEPTIDES IMPARTING CELL PERMEABILITY TO LIPID MEMBRANE STRUCTURE AND/OR ENHANCING CELL PERMEABILITY OF LIPID MEMBRANE STRUCTURE, AND LIPID MEMBRANE STRUCTURE COMPRISING LIPID BOUND TO SUCH PEPTIDE AS CONSTITUENT LIPID AND HAVING CELL PERMEABILITY OR SHOWING ENHANCED CELL PERMEABILITY 新技術説明会

外国特許コード F110006073
整理番号 S2010-0212
掲載日 2011年12月28日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2010JP072485
国際公開番号 WO 2011074578
国際出願日 平成22年12月14日(2010.12.14)
国際公開日 平成23年6月23日(2011.6.23)
優先権データ
  • 特願2009-283091 (2009.12.14) JP
発明の名称 (英語) PEPTIDES IMPARTING CELL PERMEABILITY TO LIPID MEMBRANE STRUCTURE AND/OR ENHANCING CELL PERMEABILITY OF LIPID MEMBRANE STRUCTURE, AND LIPID MEMBRANE STRUCTURE COMPRISING LIPID BOUND TO SUCH PEPTIDE AS CONSTITUENT LIPID AND HAVING CELL PERMEABILITY OR SHOWING ENHANCED CELL PERMEABILITY 新技術説明会
発明の概要(英語) Provided are peptides imparting cell permeability to a lipid membrane structure and/or enhancing the cell permeability of a lipid membrane structure, and a lipid membrane structure which comprises, as a constituent lipid, a lipid bound to such a peptide and has cell permeability or shows enhanced cell permeability. The amino acid sequences of the peptides imparting cell permeability to a lipid membrane structure and/or enhancing the cell permeability of a lipid membrane structure are represented by: LX1X2X1X1X1L, LLX2X1X1X1L and LX1X2X1X1L (wherein L represents a leucine residue; X1 represents a polar amino acid residue; and X2 represents a polar, non-charged and branched chain amino acid residue).
従来技術、競合技術の概要(英語) BACKGROUND ART
Protein, agent, nucleic acid or of a material such as, reliably to a target site in a living organism of a vector or carrier for the delivery of a performed has been actively developed. For example, for introducing the gene of interest into a target cell as a vector, retrovirus, adenovirus, adeno-associated virus such as viral vectors have been developed. However, viral vector, the difficulty of mass production, antigenicity, since problems such as toxicity, such a problem is small The neoplastic represented by a lipid membrane structure and is attracting attention.
The neoplastic cell is, in the lipid bilayer membrane prepared artificially basically constituted by a lipid membrane structure and, containing a variety of materials is fed into the target cells have the capability. The neoplastic cell is, on the surface of the antibody, protein, sugar chain by introducing functional molecules such as, improve the directivity at the target site can be the benefits of, material is included for the decomposition of the in vivo and metabolism and protected from the action of an advantage that a, at a position other than the target substance action (side effects) has an advantage of the prevention.
On the other hand, protein chemical agents and the like, of the nucleic acid material containing a lipid membrane structure, or protein or a chemical, such as nucleic acids bound to a polymer compound such as when administered into the blood, from reaching the target site from blood constitutes a big problem. In many tissues in vascular endothelial cells among the cells form a tight-junctions, gap between vascular endothelial cells and from about 4 nm to about 0.4 nm very small, the polymer compound in the blood is administered, this through the gap is difficult to reach the target site.
Therefore, the adhesive bond is formed to a target site of a vascular endothelial layer can be a lipid membrane structure and reach and have been developed, for example, albumin, albumin binding protein selected from the antibodies GP60 or anti-GP60, a peptide that promotes transcytosis in epithelial cells (Patent Document 1), from the point of connection is made, the blood-brain barrier in a peptide that promotes transcytosis (Patent Document 2), occludin protein adhesion bond formation to inhibit the synthesis of antisense oligonucleotides, lipid membrane structure or co-administered (Patent Document 3) and the like have been developed.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
  • 発明者(英語)
  • HARASHIMA Hideyoshi
  • FUJIWARA Takahiro
  • AKITA Hidetaka
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PE PG PH PL PT RO RS RU SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ MD RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記までご連絡ください

PAGE TOP

close
close
close
close
close
close